Cancer Genetics jumps on upbeat Feltl note

|About: Cancer Genetics, Inc. (CGIX)|By:, SA News Editor

Shares of Cancer Genetics (CGIX +4.8%) — which got a big lift last week on an upbeat Aegis initiation — are on the move after Feltl's Ben Haynor ups his price target to $30.50 from $17.50.

Among the catalysts cited by Haynor: CGIX's expanded relationship with Roche and the debut of the Mantle Cell Lymphoma array.